Study Initiated for Bispecific Antibody in Patients With T-cell Lymphoma

A phase 1 study from Ono Pharma USA, Inc. will examine the effects of ONO-4685, an anti-PD—1/CD3 bispecific antibody, in patients with relapsed or refractory T-cell lymphoma.

"We are excited to initiate the Phase 1 study of ONO-4685, an anti-PD-1/CD3 bispecific antibody with a novel mechanism of action, and hope that ONO-4685 will provide benefit to the patients with relapsed or refractory T-cell lymphoma in the U.S. one day," said Masahiro Katayama, Executive Vice President and US/EU Head of Clinical Development, at Ono Pharma USA, Inc., in a release.

ONO-4685 binds to PD-1 (an inhibitory receptor expressed on activated T and B cells) and CD3 (a component protein of the T-cell receptor) in the body. It was developed to treat autoimmune diseases and hematologic malignancies and has potential to treat T-cell lymphomas.

The trial will be conducted at multiple sites in the U.S. and is an open label dose escalation study.

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.